Global Ganja Report

On New Year’s Day, as retail sales of cannabis went legal in Colorado, the state's dispensaries registered well over $1 million in sales. Despite cold and wet weather, most of the 36 shops that opened that day reported long lines, with some customers waiting outdoors for hours. By the end of the first week, by which time another dozen retail outlets had opened, the figure was a whopping $5 million. More than 100 dispensaries in the Centennial State have now received licenses for retail cannabis sales and over 500 are eligible to apply. More are applying every day.

"A new industry is developing in a nascent state in Colorado," says Rachel Gillette, director of the Colorado chapter of the National Organization for the Reform of Marijuana Laws (NORML). "We're not just talking about retail sales, but a lot of other types of business associated with it—construction companies, HVAC contractors, nutrient companies, lighting and equipment sales, packaging, printers, labeling, marketing materials, websites, marijuana tourism, attorneys, payroll companies… This could represent a lot of jobs."

US Rep. Scott Perry (R-PA) on July 29 introduced a bill to legalize cannabidiol (CBD) oil on a national level, citing its effectiveness in treating seizures in children suffering from epilepsy. The "Charlotte's Web Medical Hemp Act of 2014" would remove CBD oil and "therapeutic hemp" from the federal definition of marijuana in the Controlled Substances Act. "Therapeutic hemp" is cannabis that contains no more than .3% THC and therefore produces no "high." Perry announced the bill at press conference where he was joined by the president of the national Epilepsy Foundation and advocates that included the mother of Colorado girl Charlotte Figi, whose successful treatment with  CBD  oil won national interest. Also present was Joel Stanley, one of the creators of the "Charlotte's Web" strain of marijuana used to treat Figi. Introduction of the legislation coincides with a pledge by Pennsylvania's Gov. Tom Corbett to create a state-level pilot program for families whose children require access to medical marijuana. (Jurist, July 29; PennLive, MSBC, July 28)

Missouri has some of the harshest marijuana laws in the country, but became the latest state to remove criminal penalties for simple possession arrests on May 13, when a bill passed earlier this year by the legislature became law without Governor Jay Nixon’s signature. The new law, Senate Bill 491, eliminates jail time for possession of up to 10 grams on a first offense. The new law also reduces possible sentences related to sale and cultivation, lifting the current ban on probation or parole for those with third felony offenses. However, it will not take effect until Jan. 1, 2017, and the protections against incarceration only apply to those without prior marijuana convictions. Additionally, a possession charge will remain a criminal offense, merely reduced to a Class D misdemeanor from a Class A misdemeanor. The Marijuana Policy Project is saying the new law counts as "decriminalization," but Missouri attorney and NORML board member Dan Viets, who helped draft the bill, says, "Nobody should call this decriminalization." (CelebStoner, May 16; Daily Chronic, May 15)

Arizona's Maricopa County Superior Court ruled March 21 in favor of five-year-old Zander Welton, finding that his parents and physicians may resume treating his seizure disorder with a cannabis extract. Judge Katherine Cooper said that the Arizona Medical Marijuana Act (AMMA), approved by voters in 2010, allows patients to use extracts without fear of prosecution. In October, the American Civil Liberties Union and the ACLU of Arizona sued the county on behalf of Zander and his parents, Jennifer and Jacob Welton, after Maricopa Attorney Bill Montgomery and other Arizona law enforcement agents asserted that the AMMA does not permit the use of extracts, and threatened criminal charges.

British firm GW Pharmaceuticals has won "orphan drug status"—a special category for agents developed to treat rare diseases—from the US Food and Drug Administration (FDA) for Epidiolex, a derivative of cannabidiol (CBD), to treat Dravet syndrome, a severe form epilepsy. In Utah, parents who are lobbying to import CBD-rich cannabis strains from Colorado, say they will keep up their campaign. "This changes nothing" in regard to children being able to access CBD, said Jennifer May, mother of 11-year-old Stockton, who suffers from Dravet syndrome. "On the other hand, it does lend credibility to the potential of CBD as a treatment." Like many Dravet patients, Stockton has tried dozens of pharmaceutical fixes, and run out of options. He can no longer use the toilet and has to be fed from a tube. "Orphan drug" designation qualifies GW for tax credits and exclusive rights to the drug if approved. But FDA approval for Epidiolex could take a year or more. (Salt Lake Tribune, Nov. 18)

Israeli scientists have developed a non-psychoative cannabis variety, in what is being portrayed as a boost for medical marijuana. According to Israel's Maariv newspaper, the new variety looks, smells and even tastes "the same" as psychoactive varieties. "It has the same scent, shape and taste as the original plant—it's all the same—but the numbing sensation that users are accustomed to has disappeared," said Tzahi Klein, head of development at Tikkun Olam, the firm that developed what an AFP account calls "the species." Klein adds: "Many of our patients who tried the new plant come back to us and say: 'You tricked me'"—because they assumed they had been given a placebo.

The country's leading medical marijuana advocacy group, Americans for Safe Access (ASA), filed an appeal brief Jan. 26 in the DC Circuit to compel the federal government to reclassify cannabis for medical use. In July 2011, the federal Drug Enforcement Administration (DEA) denied a petition filed in 2002 by the Coalition for Rescheduling Cannabis (CRC). The petition was denied only after the coalition sued the government for unreasonable delay. The ASA brief is an appeal of the rescheduling denial.

Earlier this month, the National Cancer Institute nodded to a growing body of studies indicating that one of the chemical compounds in cannabis slows—or stops—uncontrolled cell growth. In one study, tumors in lab mice shrank once exposed to the compound CBD. The NCI updated its website to include a reference to a "possible direct antitumor effect" from cannabis. But sometime since, the reference was removed, much to cannabis advocates' disgust.